General Toxicology Issues: Systemic

General Toxicology Issues: Systemic administration of olopatadine have been associated with untoward effects in the CNS, respiratory, and cardiovascular (including a 20-40 msec prolongation of the QTc interval in dogs) systems and pathological changes in the liver, kidney, and hea时， among other organs. However, the doses at which these effects occurred are greatly in excess of therapeutic ophthalmic doses and were associated with plasma levels much higher than those detected after ocular administration of 0.15% Olopatadine Hydrochloride Ophthalmic Solution (refer to table below). Therefore, olopatadine is not expected to cause significant adverse effects in humans following topical ocular administration of 0.2% Olopatadine
一一
Hydrochloride QD Ophthalmic Solution. The maximum daily dose of 斗. is the same as that of P

結果 (中文) 1:

一般毒理学问题︰ 全身用药的奥洛他定已与不良影响中枢神经系统、 呼吸系统疾病和心血管 （包括狗 QTc 间期延长一 20-40 毫秒） 系统和肝、 肾和 hea时，在其他器官的病理变化。然而，在这些效应发生的剂量大大超过治疗眼科剂量，均与血浆水平远高于那些检测后眼部给药的 0.15%盐酸奥洛他定滴眼液 （请参阅下表）。因此，奥洛他定预期不会造成重大不利影响人类后外用眼部给药的 0.2%奥洛他定一一盐酸 QD 滴眼液。斗的最大的每日剂量是 P 相同

結果 (中文) 3:

一般毒理学问题：奥洛他定的系统管理已与中枢神经系统、呼吸系统和心血管的不良反应，（包括20-40毫秒延长犬QTc间期）系统和肝、肾病理变化，与健康时，其他器官。然而，在这些影响发生的剂量在治疗眼科剂量和血浆水平大大超过了比0.15%盐酸奥洛他定滴眼液眼部给药后检测更高相关（见下表）。因此，奥洛他定是不会造成局部眼部给药0.2%奥洛他定人类重大不利影响一一每日滴眼液盐酸。对斗每日最大剂量。是相同的P